Skip to main content Back to Top
Advertisement

7/11/2019

Ketamine Injection

Products Affected - Description

    • Ketalar injection, Par Pharmaceuticals, 100 mg/mL, 5 mL vial, 10 count, NDC 42023-0115-10
    • Ketamine injection, Hikma, 100 mg/mL, 5 mL vial, 10 count, NDC 00143-9509-10
    • Ketamine injection, Hikma, 50 mg/mL, 10 mL vial, 10 count, NDC 00143-9508-10
    • Ketamine injection, Pfizer, 100 mg/mL, 5 mL vial, 10 count, NDC 00409-2051-05
    • Ketamine injection, Pfizer, 50 mg/mL, 10 mL vial, 10 count, NDC 00409-2053-10

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional refuses to provide availability information.
    • Par has Ketalar on shortage due to increased demand.
    • Pfizer has ketamine on shortage due to manufacturing delays.

Available Products

    • Ketalar injection, Par Pharmaceuticals, 10 mg/mL, 20 mL vial, 10 count, NDC 42023-0113-10
    • Ketalar injection, Par Pharmaceuticals, 50 mg/mL, 10 mL vial, 10 count, NDC 42023-0114-10

Estimated Resupply Dates

    • Hikma has ketamine 50 mg/mL 10 mL and 100 mg/mL 5 mL vials on allocation.
    • Pfizer has ketamine 50 mg/mL 10 mL vials on back order and the company estimates a release date of January 2020. The 100 mg/mL 5 mL vials are on back order and the company estimates a release date of November 2019.
    • Par has Ketalar 100 mg/mL 5 mL vials on back order and the company estimates a release date of mid-July 2019.

Updated

Updated July 11, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins